CEO Insights team , Abhinav Agarwal,Correspondent, CEO Insights
Mark, who has received his B.A. from The Johns Hopkins University & his Ph.D. in Cellular & Molecular Biology from the University of Wisconsin, Madison, is an acknowledged leader in the area of oncology drug discovery & translational science, and has over 25 years of experience across immune-oncology, epigenetic, and tumor cell metabolism. With over 20 research publications to his credit, he has a stellar track record in research, innovation & cross-functional leadership in organizations such as Merck Research Labs, Dana-Farber Cancer Institute, Agios Pharmaceuticals, and Novartis Institute of BioMedical Research.
Located in the heart of the Cambridge/Boston biotech ecosystem, Sai's new 8,500 square feet lab in Kendall
Mark is an acknowledged leader in the area of oncology drug discovery & translational science
Square creates opportunities for biotechs to have face-to-face collaboration with Sai scientists, and to accelerate the pace of their externalized research by reducing cycle-times. The lab provides exploratory biology capabilities using state-of-the-art platforms & technologies such as high-content microscopy, CRISPR-mediated genome editing, flow cytometry/sorting, and high-throughput patch-clamp platforms to address unique client needs. These activities include new target & biomarker identification and/or validation & establishing in vitro and cell-based assays for established targets.
The Cambridge lab serves as a vital bridge, enabling seamless integration with rest of the company's service offerings across UK and India, spanning the drug discovery & development continuum including medicinal chemistry, DMPK & toxicology, process chemistry & analytical development, and commercial scale manufacturing.
Sai Life Sciences is currently in the midst of an organization-wide initiative, Sai Nxt that is aimed at transforming the company into a new generation CDMO. With investments of over $ 150 million between 2019 and 2023, the focus is on three key areas – people & culture, processes & automation, infrastructure & scientific capabilities.